Avner Rotman - Jan 1, 2023 Form 3/A - Amendment Insider Report for BiondVax Pharmaceuticals Ltd. (BVXV)

Role
Director
Signature
/s/ Avner Rotman
Stock symbol
BVXV
Transactions as of
Jan 1, 2023
Transactions value $
$0
Form type
3/A - Amendment
Date filed
1/23/2023, 07:00 AM
Date Of Original Report
Jan 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BVXV Ordinary Shares 139K Jan 1, 2023 Direct F1
holding BVXV Ordinary Shares 66.8K Jan 1, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BVXV Stock Options (right to buy) Jan 1, 2023 Ordinary Shares 720K $0.18 Direct F1, F2
holding BVXV Stock Options (right to buy) Jan 1, 2023 Ordinary Shares 1M $0.17 Direct F1, F3
holding BVXV Restricted Share Units Jan 1, 2023 Ordinary Shares 133K Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
F2 Stock options were granted on March 24, 2020 and are fully vested.
F3 Stock options were granted on April 6, 2021, and vest on a monthly basis during a period of three years.
F4 Restricted share units were granted on April 6, 2021, and vest on a monthly basis during a period of three years.
F5 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share.